middle.news
Neurizon Surpasses 50% Dosing in Expanded HEALEY ALS Trial
9:07am on Friday 12th of June, 2026 AEST
•
Biotechnology
Read Story
Neurizon Surpasses 50% Dosing in Expanded HEALEY ALS Trial
9:07am on Friday 12th of June, 2026 AEST
Key Points
More than 50% of Regimen I participants dosed in HEALEY ALS trial
Cohort expanded from 160 to 240 due to strong recruitment momentum
167 participants assigned and 129 dosed as of 9 June 2026
78 clinical sites activated across the United States
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE